NGeneBio Co. Ltd.
NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myelopro… Read more
Market Cap & Net Worth: NGeneBio Co. Ltd. (354200)
NGeneBio Co. Ltd. (KQ:354200) has a market capitalization of $35.23 Million (₩51.58 Billion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #24568 globally and #1431 in its home market, demonstrating a 5.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NGeneBio Co. Ltd.'s stock price ₩2060.00 by its total outstanding shares 25038128 (25.04 Million).
NGeneBio Co. Ltd. Market Cap History: 2020 to 2026
NGeneBio Co. Ltd.'s market capitalization history from 2020 to 2026. Data shows change from $503.27 Million to $35.23 Million (-37.39% CAGR).
Index Memberships
NGeneBio Co. Ltd. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.01% | #716 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.01% | #716 of 1384 |
Weight: NGeneBio Co. Ltd.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
NGeneBio Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NGeneBio Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
NGeneBio Co. Ltd.'s market cap is 0.00 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $503.27 Million | $2.48 Billion | -$8.23 Billion | 0.20x | N/A |
| 2021 | $262.15 Million | $7.16 Billion | -$8.43 Billion | 0.04x | N/A |
| 2022 | $150.17 Million | $11.02 Billion | -$9.79 Billion | 0.01x | N/A |
| 2023 | $89.97 Million | $4.35 Billion | -$12.77 Billion | 0.02x | N/A |
| 2024 | $28.08 Million | $5.69 Billion | -$12.63 Billion | 0.00x | N/A |
Competitor Companies of 354200 by Market Capitalization
Companies near NGeneBio Co. Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to NGeneBio Co. Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
NGeneBio Co. Ltd. Historical Marketcap From 2020 to 2026
Between 2020 and today, NGeneBio Co. Ltd.'s market cap moved from $503.27 Million to $ 35.23 Million, with a yearly change of -37.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩35.23 Million | +41.10% |
| 2025 | ₩24.97 Million | -11.08% |
| 2024 | ₩28.08 Million | -68.79% |
| 2023 | ₩89.97 Million | -40.09% |
| 2022 | ₩150.17 Million | -42.72% |
| 2021 | ₩262.15 Million | -47.91% |
| 2020 | ₩503.27 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of NGeneBio Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.23 Million USD |
| MoneyControl | $35.23 Million USD |
| MarketWatch | $35.23 Million USD |
| marketcap.company | $35.23 Million USD |
| Reuters | $35.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.